Kevin van Veenhuijzen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin van Veenhuijzen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ludo Van Den Bosch
Department of Neurology University Medical Center Utrecht, Utrecht University Utrecht the Netherlands
8 shared publications - Henk-Jan Westeneng
Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
7 shared publications - Jan Herman Veldink
Department of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, The Netherlands
4 shared publications - Harold H. G. Tan
Department of Neurology, UMC Utrecht Brain Center University Medical Center Utrecht Utrecht The Netherlands
3 shared publications Michael A. van Es
Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands
3 shared publications- Michael A. van Es
Department of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 121, 105963
Patterns of altered in vivo brain metabolism in patients with amyotrophic lateral sclerosis (ALS) and asymptomatic C9orf72 mutation carriers: a cross-sectional 1H and 31P magnetic resonance spectroscopic 7T imaging study
- 15 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 121, 105963
Open AccessPatterns of altered in vivo brain metabolism in patients with amyotrophic lateral sclerosis (ALS) and asymptomatic C9orf72 mutation carriers: a cross-sectional 1H and 31P magnetic resonance spectroscopic 7T imaging study
- Open Access
Resting-state EEG oscillations are reduced in asymptomatic C9orf72 repeat expansion carriers
Objective: We investigated the signature of the C9orf72 repeat expansion on resting-state cortical activity in asymptomatic individuals and explored its relationship with structural, gene expression, and cognitive measures. Methods: High-density resting-state EEG was compared between 90 asymptomatic family members of patients with familial amyotrophic lateral sclerosis (ALS), dichotomised into carriers of the pathological C9orf72 repeat expansion (N = 37) and non-carrier controls (N = 53). Periodic (oscillatory) and aperiodic (1/f) components of the power spectrum were analysed at the sensor- and source-level. Regional EEG power changes were correlated with C9orf72 expression from the Allen Human Brain Atlas, cortical MRI thickness and performance on the Complementary Cognitive ALS Screen (C-CAS). Results: Asymptomatic carriers exhibited significantly lower periodic power in the α and β frequency bands (10-30 Hz) across posterior cortical regions, including the parietal, occipital, and temporal lobes. The magnitude of this power reduction was associated with increased C9orf72 expression and reduced cortical thickness in the same regions. In carriers, reduced β-band power was associated with poorer performance on Visuoconstructive Immediate and Body Representation tasks. The aperiodic component of the EEG power did not differ between groups. Interpretation: In asymptomatic C9orf72 repeat expansion carriers, resting-state EEG reveals differences in oscillatory power in the posterior brain regions. The correlational findings suggest that C9orf72 repeat expansion may be involved in functional and structural changes in the posterior cerebral cortex, which may contribute to deficits in tasks requiring visuospatial processing.
Open AccessResting-state EEG oscillations are reduced in asymptomatic C9orf72 repeat expansion carriers
Objective: We investigated the signature of the C9orf72 repeat expansion on resting-state cortical activity in asymptomatic individuals and explored its relationship with structural, gene expression, and cognitive measures. Methods: High-density resting-state EEG was compared between 90 asymptomatic family members of patients with familial amyotrophic lateral sclerosis (ALS), dichotomised into carriers of the pathological C9orf72 repeat expansion (N = 37) and non-carrier controls (N = 53). Periodic (oscillatory) and aperiodic (1/f) components of the power spectrum were analysed at the sensor- and source-level. Regional EEG power changes were correlated with C9orf72 expression from the Allen Human Brain Atlas, cortical MRI thickness and performance on the Complementary Cognitive ALS Screen (C-CAS). Results: Asymptomatic carriers exhibited significantly lower periodic power in the α and β frequency bands (10-30 Hz) across posterior cortical regions, including the parietal, occipital, and temporal lobes. The magnitude of this power reduction was associated with increased C9orf72 expression and reduced cortical thickness in the same regions. In carriers, reduced β-band power was associated with poorer performance on Visuoconstructive Immediate and Body Representation tasks. The aperiodic component of the EEG power did not differ between groups. Interpretation: In asymptomatic C9orf72 repeat expansion carriers, resting-state EEG reveals differences in oscillatory power in the posterior brain regions. The correlational findings suggest that C9orf72 repeat expansion may be involved in functional and structural changes in the posterior cerebral cortex, which may contribute to deficits in tasks requiring visuospatial processing.
- Open Access
- 25 July 2025
- Published by Wiley in Human Brain Mapping
- Vol. 46 (11) , e70275
Altered EEG Response of the Parietal Network in Asymptomatic C9orf72 Carriers
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by motor neuron degeneration. Around 10% of cases have a genetic basis, with the C9orf72 hexanucleotide repeat expansion being the most common cause in individuals of European ancestry. Detecting early alterations in at‐risk individuals could aid in identifying biomarkers for timely diagnosis and intervention. In this study, we investigated electrophysiological changes in asymptomatic C9orf72 mutation carriers using EEG, focusing on cognitive and motor networks, as these individuals are at risk of developing impairments in both domains. This study included 87 asymptomatic family members (AFM) of patients with familial C9orf72 ALS, comprising 37 individuals carrying the pathological repeat expansion (C9+) and 50 without it (C9−). High‐density EEG was recorded during the sustained attention to response task (SART), which is a Go/NoGo paradigm that engages the frontoparietal and motor networks. Task performance was recorded and six behavioral measures were extracted: NoGo accuracy, Go accuracy, total accuracy, anticipation error, average response time, and response time variability. Analyses were conducted on EEG data in both sensor‐ and source‐space, using stimulus‐ and response‐locked data. The stimulus‐locked Go and NoGo data were analysed within two time windows: 180–350 ms (N2) and 300–600 ms (P3), while response‐locked Go data were analysed within a −100 to 100 ms time window. Linear mixed models were used to quantify differences between groups, incorporating familial pedigree to control for between‐subject dependencies. While the two groups did not significantly differ in any SART performance measures, EEG analyses revealed differences. During the stimulus‐locked N2, significant differences were observed in sensor‐space, primarily in central electrodes during both NoGo and Go conditions, with C9+ AFM exhibiting an increased negative potential. Source analysis confirmed these findings and localized the increased activity in the bilateral precuneus and superior parietal regions. Further analysis of the response‐locked data supported the involvement of the same posterior regions. No significant relationships were found between these EEG observations and SART performance. These findings provide the first evidence of EEG changes in AFM carrying the C9orf72 repeat expansion. The observed functional changes in the parietal regions may reflect genotype‐related effects on the motor control network, potentially contributing to early pathophysiology. In contrast, clinical assessments and task performance did not differ between groups, suggesting that our EEG findings may hold promise as biomarkers for monitoring the risk of conversion to symptomatic disease and warrant further exploration to assess their predictive value for future symptom onset.
- 25 July 2025
- Published by Wiley in Human Brain Mapping
- Vol. 46 (11) , e70275
Open AccessAltered EEG Response of the Parietal Network in Asymptomatic C9orf72 Carriers
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by motor neuron degeneration. Around 10% of cases have a genetic basis, with the C9orf72 hexanucleotide repeat expansion being the most common cause in individuals of European ancestry. Detecting early alterations in at‐risk individuals could aid in identifying biomarkers for timely diagnosis and intervention. In this study, we investigated electrophysiological changes in asymptomatic C9orf72 mutation carriers using EEG, focusing on cognitive and motor networks, as these individuals are at risk of developing impairments in both domains. This study included 87 asymptomatic family members (AFM) of patients with familial C9orf72 ALS, comprising 37 individuals carrying the pathological repeat expansion (C9+) and 50 without it (C9−). High‐density EEG was recorded during the sustained attention to response task (SART), which is a Go/NoGo paradigm that engages the frontoparietal and motor networks. Task performance was recorded and six behavioral measures were extracted: NoGo accuracy, Go accuracy, total accuracy, anticipation error, average response time, and response time variability. Analyses were conducted on EEG data in both sensor‐ and source‐space, using stimulus‐ and response‐locked data. The stimulus‐locked Go and NoGo data were analysed within two time windows: 180–350 ms (N2) and 300–600 ms (P3), while response‐locked Go data were analysed within a −100 to 100 ms time window. Linear mixed models were used to quantify differences between groups, incorporating familial pedigree to control for between‐subject dependencies. While the two groups did not significantly differ in any SART performance measures, EEG analyses revealed differences. During the stimulus‐locked N2, significant differences were observed in sensor‐space, primarily in central electrodes during both NoGo and Go conditions, with C9+ AFM exhibiting an increased negative potential. Source analysis confirmed these findings and localized the increased activity in the bilateral precuneus and superior parietal regions. Further analysis of the response‐locked data supported the involvement of the same posterior regions. No significant relationships were found between these EEG observations and SART performance. These findings provide the first evidence of EEG changes in AFM carrying the C9orf72 repeat expansion. The observed functional changes in the parietal regions may reflect genotype‐related effects on the motor control network, potentially contributing to early pathophysiology. In contrast, clinical assessments and task performance did not differ between groups, suggesting that our EEG findings may hold promise as biomarkers for monitoring the risk of conversion to symptomatic disease and warrant further exploration to assess their predictive value for future symptom onset.
- Open Access
- 13 March 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (4) , 1-12
Cognitive impairment within and beyond the FTD spectrum in ALS: development of a complementary cognitive screen
Objective: To investigate cognitive impairments in amyotrophic lateral sclerosis (ALS), extending both within and beyond the established frontotemporal dementia (FTD) spectrum, using the Complementary Cognitive ALS Screen (C-CAS). Methods: The C-CAS, designed to complement the Edinburgh cognitive and behavioural ALS screen (ECAS), explores cognitive (sub)domains not investigated by the ECAS. Normative data were collected, and models adjusted for age, sex, and education level were developed. Item scores below the 5th percentile in controls were considered abnormal. A sum score was constructed, and C-CAS impairments were compared between ALS patients and controls, and to ECAS impairments. Results: Data from 314 controls and 184 ALS patients were analyzed. The C-CAS is feasible, well-tolerated, and takes 15–20 min to complete. ALS patients performed worse across all 12 items. Within the FTD spectrum, impairments in social cognition, inhibition, and cognitive flexibility were identified in up to 16%, 14%, and 12% of ALS patients, respectively, with minimal overlap with ECAS impairments. Beyond the FTD spectrum, impairments were found in visuoconstruction, incidental non-verbal memory and body orientation (13% each), with minimal overlap with ECAS memory or visuospatial impairments. Overall, 24% of the ALS patients obtained an abnormal C-CAS sum score. Compared to the ECAS, the C-CAS detected additional impairments in 15% of ALS patients. Item-specific and sum score results based on normative data can be accessed at (https://apps4mnd.com/ccas/). Interpretation: We identified cognitive impairments in ALS within and beyond the FTD spectrum not captured by existing screening tools. The C-CAS complements the ECAS, improving personalized counseling and research stratification in ALS.
- 13 March 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (4) , 1-12
Open AccessCognitive impairment within and beyond the FTD spectrum in ALS: development of a complementary cognitive screen
Objective: To investigate cognitive impairments in amyotrophic lateral sclerosis (ALS), extending both within and beyond the established frontotemporal dementia (FTD) spectrum, using the Complementary Cognitive ALS Screen (C-CAS). Methods: The C-CAS, designed to complement the Edinburgh cognitive and behavioural ALS screen (ECAS), explores cognitive (sub)domains not investigated by the ECAS. Normative data were collected, and models adjusted for age, sex, and education level were developed. Item scores below the 5th percentile in controls were considered abnormal. A sum score was constructed, and C-CAS impairments were compared between ALS patients and controls, and to ECAS impairments. Results: Data from 314 controls and 184 ALS patients were analyzed. The C-CAS is feasible, well-tolerated, and takes 15–20 min to complete. ALS patients performed worse across all 12 items. Within the FTD spectrum, impairments in social cognition, inhibition, and cognitive flexibility were identified in up to 16%, 14%, and 12% of ALS patients, respectively, with minimal overlap with ECAS impairments. Beyond the FTD spectrum, impairments were found in visuoconstruction, incidental non-verbal memory and body orientation (13% each), with minimal overlap with ECAS memory or visuospatial impairments. Overall, 24% of the ALS patients obtained an abnormal C-CAS sum score. Compared to the ECAS, the C-CAS detected additional impairments in 15% of ALS patients. Item-specific and sum score results based on normative data can be accessed at (https://apps4mnd.com/ccas/). Interpretation: We identified cognitive impairments in ALS within and beyond the FTD spectrum not captured by existing screening tools. The C-CAS complements the ECAS, improving personalized counseling and research stratification in ALS.
- Open Access
- 2 November 2024
- Published by Wiley in Annals of Neurology
- Vol. 97 (2) , 281-295
Longitudinal Magnetic Resonance Imaging in Asymptomatic C9orf72 Mutation Carriers Distinguishes Phenoconverters to Amyotrophic Lateral Sclerosis or Amyotrophic Lateral Sclerosis With Frontotemporal Dementia
Objective: We prospectively studied asymptomatic C9orf72 mutation carriers, identifying those developing amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).Methods: We enrolled 56 asymptomatic family members (AFM) with a C9orf72 mutation (AFM C9+), 132 non‐carriers (AFM C9−), and 359 population‐based controls. Using 3 T magnetic resonance imaging, we measured cortical thickness, gyrification, and subcortical volumes longitudinally. Linear mixed‐effects models on non‐converting AFM C9+ scans (n = 107) created a reference for these measurements, establishing individual atrophy patterns. Atrophy patterns from presymptomatic phenoconverters (n = 10 scans) served as a template for group comparisons and similarity assessments. Similarity with phenoconverters was quantified using Dice similarity coefficient (DSC) for cortical and Kullback–Leibler similarity (KLS) for subcortical measures. Using longitudinal similarity assessments, we predicted when participants would reach the average similarity level of phenoconverters at their first post‐onset scan.Results: Five AFM C9+ converted to ALS or ALS‐FTD. Up to 6 years before symptoms, these phenoconverters exhibited significant atrophy in frontal, temporal, parietal, and cingulate cortex, along with smaller thalamus, hippocampus, and amygdala compared to other AFM C9+. Some non‐converted AFM C9+ had high DSC and KLS, approaching values of phenoconverters, whereas others, along with AFM C9− and controls, had lower values. At age 80, we predicted 27.9% (95% confidence interval, 13.2–40.1%) of AFM C9+ and no AFM C9− would reach the same DSC as phenoconverters.Interpretation: Distinctive atrophy patterns are visible years before symptom onset on presymptomatic scans of phenoconverters. Combining baseline and follow‐up similarity measures may serve as a promising imaging biomarker for identifying those at risk of ALS or ALS‐FTD. ANN NEUROL 2025;97:281–295
- 2 November 2024
- Published by Wiley in Annals of Neurology
- Vol. 97 (2) , 281-295
Open AccessLongitudinal Magnetic Resonance Imaging in Asymptomatic C9orf72 Mutation Carriers Distinguishes Phenoconverters to Amyotrophic Lateral Sclerosis or Amyotrophic Lateral Sclerosis With Frontotemporal Dementia
Objective: We prospectively studied asymptomatic C9orf72 mutation carriers, identifying those developing amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).Methods: We enrolled 56 asymptomatic family members (AFM) with a C9orf72 mutation (AFM C9+), 132 non‐carriers (AFM C9−), and 359 population‐based controls. Using 3 T magnetic resonance imaging, we measured cortical thickness, gyrification, and subcortical volumes longitudinally. Linear mixed‐effects models on non‐converting AFM C9+ scans (n = 107) created a reference for these measurements, establishing individual atrophy patterns. Atrophy patterns from presymptomatic phenoconverters (n = 10 scans) served as a template for group comparisons and similarity assessments. Similarity with phenoconverters was quantified using Dice similarity coefficient (DSC) for cortical and Kullback–Leibler similarity (KLS) for subcortical measures. Using longitudinal similarity assessments, we predicted when participants would reach the average similarity level of phenoconverters at their first post‐onset scan.Results: Five AFM C9+ converted to ALS or ALS‐FTD. Up to 6 years before symptoms, these phenoconverters exhibited significant atrophy in frontal, temporal, parietal, and cingulate cortex, along with smaller thalamus, hippocampus, and amygdala compared to other AFM C9+. Some non‐converted AFM C9+ had high DSC and KLS, approaching values of phenoconverters, whereas others, along with AFM C9− and controls, had lower values. At age 80, we predicted 27.9% (95% confidence interval, 13.2–40.1%) of AFM C9+ and no AFM C9− would reach the same DSC as phenoconverters.Interpretation: Distinctive atrophy patterns are visible years before symptom onset on presymptomatic scans of phenoconverters. Combining baseline and follow‐up similarity measures may serve as a promising imaging biomarker for identifying those at risk of ALS or ALS‐FTD. ANN NEUROL 2025;97:281–295
- Open Access
- 23 July 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (2) , e209603
Association Between Hypothalamic Volume and Metabolism, Cognition, and Behavior in Patients With Amyotrophic Lateral Sclerosis
Background and ObjectivesDysfunction of energy metabolism, cognition, and behavior are important nonmotor symptoms of amyotrophic lateral sclerosis (ALS), negatively affecting survival and quality of life, but poorly understood. Neuroimaging is ideally ...
- 23 July 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (2) , e209603
Open AccessAssociation Between Hypothalamic Volume and Metabolism, Cognition, and Behavior in Patients With Amyotrophic Lateral Sclerosis
Background and ObjectivesDysfunction of energy metabolism, cognition, and behavior are important nonmotor symptoms of amyotrophic lateral sclerosis (ALS), negatively affecting survival and quality of life, but poorly understood. Neuroimaging is ideally ...
- Open Access
- 25 December 2022
- Published by Wiley in Annals of Neurology
- Vol. 93 (4) , 668-680
Longitudinal Effects of Asymptomatic C9orf72 Carriership on Brain Morphology
Objective: We investigated effects of C9orf72 repeat expansion and gene expression on longitudinal cerebral changes before symptom onset.Methods: We enrolled 79 asymptomatic family members (AFMs) from 9 families with C9orf72 repeat expansion. Twenty‐eight AFMs carried the mutation (C9+). Participants had up to 3 magnetic resonance imaging (MRI) scans, after which we compared motor cortex and motor tracts between C9+ and C9− AFMs using mixed effects models, incorporating kinship to correct for familial relations and lessen effects of other genetic factors. We also compared cortical, subcortical, cerebellar, and connectome structural measurements in a hypothesis‐free analysis. We correlated regional C9orf72 expression in donor brains with the pattern of cortical thinning in C9+ AFMs using meta‐regression. For comparison, we included 42 C9+ and 439 C9− patients with amyotrophic lateral sclerosis (ALS) in this analysis.Results: C9+ AFM motor cortex had less gyrification and was thinner than in C9− AFMs, without differences in motor tracts. Whole brain analysis revealed thinner cortex and less gyrification in parietal, occipital, and temporal regions, smaller thalami and right hippocampus, and affected frontotemporal connections. Thinning of bilateral precentral, precuneus, and left superior parietal cortex was faster in C9+ than in C9− AFMs. Higher C9orf72 expression correlated with thinner cortex in both C9+ AFMs and C9+ ALS patients.Interpretation: In asymptomatic C9orf72 repeat expansion carriers, brain MRI reveals widespread features suggestive of impaired neurodevelopment, along with faster decline of motor and parietal cortex than found in normal aging. C9orf72 expression might play a role in cortical development, and consequently explain the specific brain abnormalities of mutation carriers. ANN NEUROL 2023;93:668–680
- 25 December 2022
- Published by Wiley in Annals of Neurology
- Vol. 93 (4) , 668-680
Open AccessLongitudinal Effects of Asymptomatic C9orf72 Carriership on Brain Morphology
Objective: We investigated effects of C9orf72 repeat expansion and gene expression on longitudinal cerebral changes before symptom onset.Methods: We enrolled 79 asymptomatic family members (AFMs) from 9 families with C9orf72 repeat expansion. Twenty‐eight AFMs carried the mutation (C9+). Participants had up to 3 magnetic resonance imaging (MRI) scans, after which we compared motor cortex and motor tracts between C9+ and C9− AFMs using mixed effects models, incorporating kinship to correct for familial relations and lessen effects of other genetic factors. We also compared cortical, subcortical, cerebellar, and connectome structural measurements in a hypothesis‐free analysis. We correlated regional C9orf72 expression in donor brains with the pattern of cortical thinning in C9+ AFMs using meta‐regression. For comparison, we included 42 C9+ and 439 C9− patients with amyotrophic lateral sclerosis (ALS) in this analysis.Results: C9+ AFM motor cortex had less gyrification and was thinner than in C9− AFMs, without differences in motor tracts. Whole brain analysis revealed thinner cortex and less gyrification in parietal, occipital, and temporal regions, smaller thalami and right hippocampus, and affected frontotemporal connections. Thinning of bilateral precentral, precuneus, and left superior parietal cortex was faster in C9+ than in C9− AFMs. Higher C9orf72 expression correlated with thinner cortex in both C9+ AFMs and C9+ ALS patients.Interpretation: In asymptomatic C9orf72 repeat expansion carriers, brain MRI reveals widespread features suggestive of impaired neurodevelopment, along with faster decline of motor and parietal cortex than found in normal aging. C9orf72 expression might play a role in cortical development, and consequently explain the specific brain abnormalities of mutation carriers. ANN NEUROL 2023;93:668–680
- Open Access
- 20 September 2022
- Published by Wiley in Annals of Neurology
- Vol. 92 (6) , 1030-1045
MRI Clustering Reveals Three ALS Subtypes With Unique Neurodegeneration Patterns
Objective: The purpose of this study was to identify subtypes of amyotrophic lateral sclerosis (ALS) by comparing patterns of neurodegeneration using brain magnetic resonance imaging (MRI) and explore their phenotypes.Methods: We performed T1‐weighted and diffusion tensor imaging in 488 clinically well‐characterized patients with ALS and 338 control subjects. Measurements of whole‐brain cortical thickness and white matter connectome fractional anisotropy were adjusted for disease‐unrelated variation. A probabilistic network‐based clustering algorithm was used to divide patients into subgroups of similar neurodegeneration patterns. Clinical characteristics and cognitive profiles were assessed for each subgroup. In total, 512 follow‐up scans were used to validate clustering results longitudinally.Results: The clustering algorithm divided patients with ALS into 3 subgroups of 187, 163, and 138 patients. All subgroups displayed involvement of the precentral gyrus and are characterized, respectively, by (1) pure motor involvement (pure motor cluster [PM]), (2) orbitofrontal and temporal involvement (frontotemporal cluster [FT]), and (3) involvement of the posterior cingulate cortex, parietal white matter, temporal operculum, and cerebellum (cingulate‐parietal–temporal cluster [CPT]). These subgroups had significantly distinct clinical profiles regarding male‐to‐female ratio, age at symptom onset, and frequency of bulbar symptom onset. FT and CPT revealed higher rates of cognitive impairment on the Edinburgh cognitive and behavioral ALS screen (ECAS). Longitudinally, clustering remained stable: at 90.4% of their follow‐up visits, patients clustered in the same subgroup as their baseline visit.Interpretation: ALS can manifest itself in 3 main patterns of cerebral neurodegeneration, each associated with distinct clinical characteristics and cognitive profiles. Besides the pure motor and frontotemporal dementia (FTD)‐like variants of ALS, a new neuroimaging phenotype has emerged, characterized by posterior cingulate, parietal, temporal, and cerebellar involvement. ANN NEUROL 2022;92:1030–1045
- 20 September 2022
- Published by Wiley in Annals of Neurology
- Vol. 92 (6) , 1030-1045
Open AccessMRI Clustering Reveals Three ALS Subtypes With Unique Neurodegeneration Patterns
Objective: The purpose of this study was to identify subtypes of amyotrophic lateral sclerosis (ALS) by comparing patterns of neurodegeneration using brain magnetic resonance imaging (MRI) and explore their phenotypes.Methods: We performed T1‐weighted and diffusion tensor imaging in 488 clinically well‐characterized patients with ALS and 338 control subjects. Measurements of whole‐brain cortical thickness and white matter connectome fractional anisotropy were adjusted for disease‐unrelated variation. A probabilistic network‐based clustering algorithm was used to divide patients into subgroups of similar neurodegeneration patterns. Clinical characteristics and cognitive profiles were assessed for each subgroup. In total, 512 follow‐up scans were used to validate clustering results longitudinally.Results: The clustering algorithm divided patients with ALS into 3 subgroups of 187, 163, and 138 patients. All subgroups displayed involvement of the precentral gyrus and are characterized, respectively, by (1) pure motor involvement (pure motor cluster [PM]), (2) orbitofrontal and temporal involvement (frontotemporal cluster [FT]), and (3) involvement of the posterior cingulate cortex, parietal white matter, temporal operculum, and cerebellum (cingulate‐parietal–temporal cluster [CPT]). These subgroups had significantly distinct clinical profiles regarding male‐to‐female ratio, age at symptom onset, and frequency of bulbar symptom onset. FT and CPT revealed higher rates of cognitive impairment on the Edinburgh cognitive and behavioral ALS screen (ECAS). Longitudinally, clustering remained stable: at 90.4% of their follow‐up visits, patients clustered in the same subgroup as their baseline visit.Interpretation: ALS can manifest itself in 3 main patterns of cerebral neurodegeneration, each associated with distinct clinical characteristics and cognitive profiles. Besides the pure motor and frontotemporal dementia (FTD)‐like variants of ALS, a new neuroimaging phenotype has emerged, characterized by posterior cingulate, parietal, temporal, and cerebellar involvement. ANN NEUROL 2022;92:1030–1045